Lilly's Olumiant To Be EU's First RA JAK Inhibitor, But Pricing Is Key

Eli Lilly's Olumiant (baricitinib) has won a green light from the European Medicines Agency's CHMP, for treating rheumatoid arthritis. It has advantages over future rival and fellow JAK inhibitor Xeljanz, but pricing will be key for competing against more established treatments.